Top Markets
Coin of the day
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Clasificación en acciones #28998
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Precio por acción
$0.04406501
Última sincronización: 2024-07-09
Capitalización bursátil
$23.47M
Cambio (1 día)
-0.48%
Cambio (1 año)
0.00%
País
SE
Comercio InDex Pharmaceuticals Holding AB (publ) (INDEX)

Categoría

Ganancias de InDex Pharmaceuticals Holding AB (publ) (INDEX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di InDex Pharmaceuticals Holding AB (publ), gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de InDex Pharmaceuticals Holding AB (publ) desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH